![]() | |
Monoclonal antibody | |
---|---|
Type | Whole antibody |
Source | Humanized (from rat) |
Target | CD52 |
Clinical data | |
Trade names | Campath, Mabcampath, Lemtrada, others |
AHFS/ Drugs.com | Monograph |
MedlinePlus | a608053 |
License data |
|
Pregnancy category |
|
Routes of administration | Intravenous infusion |
Legal status | |
Legal status | |
Pharmacokinetic data | |
Elimination half-life | ~288 hrs |
Chemical and physical data | |
Formula | C6468H10066N1732O2005S40 |
Molar mass | 145454.20 g·mol−1 |
![]() ![]() |
Alemtuzumab, sold under the brand names Campath and Lemtrada among others, is a medication used to treat chronic lymphocytic leukemia (CLL) and multiple sclerosis. [1] In CLL, it has been used as both a first line and second line treatment. [1] In MS it is generally only recommended if other treatments have not worked. [1] It is given by injection into a vein or under the skin. [1]
Common side effects include low blood cells, infusion reactions, infection, nausea, diarrhea, and trouble sleeping. [2] People taking the medication should not get live vaccines. [2] Use in pregnancy may harm the baby. [2] It is a monoclonal antibody that binds to CD52, a protein present on lymphocytes, resulting in their destruction. [3]
Alemtuzumab was approved for medical use in the United States and Europe in 2001. [1] [4] The brand approved for CLL in Europe; however, was withdrawn while a new brand was approved for MS. [4] [3] In the United Kingdom a via of 12 mg costs the NHS about £7,000 as of 2021. [5] This amount in the United States is about 27,700 USD. [6]
![]() | |
Monoclonal antibody | |
---|---|
Type | Whole antibody |
Source | Humanized (from rat) |
Target | CD52 |
Clinical data | |
Trade names | Campath, Mabcampath, Lemtrada, others |
AHFS/ Drugs.com | Monograph |
MedlinePlus | a608053 |
License data |
|
Pregnancy category |
|
Routes of administration | Intravenous infusion |
Legal status | |
Legal status | |
Pharmacokinetic data | |
Elimination half-life | ~288 hrs |
Chemical and physical data | |
Formula | C6468H10066N1732O2005S40 |
Molar mass | 145454.20 g·mol−1 |
![]() ![]() |
Alemtuzumab, sold under the brand names Campath and Lemtrada among others, is a medication used to treat chronic lymphocytic leukemia (CLL) and multiple sclerosis. [1] In CLL, it has been used as both a first line and second line treatment. [1] In MS it is generally only recommended if other treatments have not worked. [1] It is given by injection into a vein or under the skin. [1]
Common side effects include low blood cells, infusion reactions, infection, nausea, diarrhea, and trouble sleeping. [2] People taking the medication should not get live vaccines. [2] Use in pregnancy may harm the baby. [2] It is a monoclonal antibody that binds to CD52, a protein present on lymphocytes, resulting in their destruction. [3]
Alemtuzumab was approved for medical use in the United States and Europe in 2001. [1] [4] The brand approved for CLL in Europe; however, was withdrawn while a new brand was approved for MS. [4] [3] In the United Kingdom a via of 12 mg costs the NHS about £7,000 as of 2021. [5] This amount in the United States is about 27,700 USD. [6]